EllumGet notified

BPC-157 / KPV stack: what's in it

By Ellum EditorialPublished Updated AI use

The short answer

BPC-157 / KPV stack combines BPC-157 and KPV.

  • What it is

    Gut-focused stack; variants add LL-37 or TB-500.

  • What people look into

    Muscle and exercise, skin and hair

  • What studies found

    Most findings on BPC-157 come from rats and cells, and no human trial has posted results yet.[1][2][3]

    Results for one compound don't tell you what the two do together.

The parts

  • BPC-157 Index

    Not FDA-approved · advisory vote July 2026 · no FDA decision

    WADA 2026: S0

    Papers on animals103
    Lab-dish (cell) papers1
    Papers PubMed tags as about people55
    Registered trials (ClinicalTrials.gov)2 of 3 search results name BPC-157
    Randomized trials in peoplenone found

  • KPV Index

    Not FDA-approved · advisory vote July 2026 · no FDA decision

Bars are counts of papers or trials; a longer bar means more studies, not better results. Study counts auto-counted from PubMed tags and ClinicalTrials.gov in the Ellum research database, as of October 6, 2026 (not reviewed; a paper can carry more than one tag). Papers PubMed tags as about people: includes reviews and case reports; not randomized trials. All bars share one scale. Each count is for that part alone.

What's in it

BPC-157 is a lab-made chain of fifteen amino acids, based on a protein said to be in stomach juice.[4] KPV is a tiny lab-made peptide, the last three amino acids of a hormone the body makes.[5]

What studies found

The study findings below come from our BPC-157 page. They are not a review of KPV or the combination.

Studies of BPC-157 found effects in cells and in rats: in a dish, rat tendon cells moved and spread faster, and in rats, cut Achilles tendons regained strength and alkali skin burns closed sooner.[6][7][8] In rats, BPC-157 was linked to healing of chemically induced colitis and of a bowel join, and to less nerve damage in a toxic model used to study multiple sclerosis.[9] These are measured outcomes in animal models, not results in patients.[1]

Safety

The safety notes below come from our BPC-157 page. They are not a safety review of KPV or the combination.

BPC-157 has two registered Phase 1 trials with a safety aim, one in healthy volunteers and a pilot after rotator cuff surgery, and neither has posted results.[2][3] A 2019 review found few studies reporting adverse reactions, but most studies were in small rodents.[1] Long-term safety in people is unknown.[1][2]

Rat and lab studies found effects on blood vessels and blood clotting that remain open questions for people.[10][11][12][13] In rats given aspirin, clopidogrel or cilostazol, BPC-157 largely reversed those drugs' effect on platelet clumping.[12] In other rat studies, BPC-157 reduced bleeding time after tail amputation, including in rats given heparin, warfarin or aspirin.[13] Whether these effects occur in people who take blood thinners has not been reported in a human trial.[1][2]

BPC-157 liver findings come from rats whose livers were injured on purpose.[14][15] In rats with tied bile ducts, liver enzyme values and liver damage were lower with BPC-157.[14] These are injury models, not tests of liver safety in people.[14][1]

Key point

Long-term effects of BPC-157 in humans are unknown, and no human trial has posted results.[1][2][3]

Regulatory status by component

Not FDA-approved How we label status

  • As of October 4, 2026, BPC-157 is not FDA-approved. On July 23, 2026, FDA's compounding advisory committee voted to recommend adding it to the 503A bulks list; FDA staff had recommended against it. FDA has not proposed that change. See BPC-157 in the Index →
  • As of October 4, 2026, KPV is not FDA-approved. On July 23, 2026, FDA's compounding advisory committee voted to recommend adding it to the 503A bulks list; FDA staff had recommended against it. FDA has not proposed that change. See KPV in the Index →

Status as of October 4, 2026

As a combination
No category as a combination (see components)
  • BPC-157: as of October 4, 2026 · source
  • KPV: as of October 4, 2026 · source

Timeline

Scroll sideways to see all columns.

DateWhat happenedSource
Federal Register notice of an FDA Pharmacy Compounding Advisory Committee meeting lists BPC-157 and KPV among bulk drug substances under consideration for the 503A bulks list.Federal Register
FDA lists BPC-157 and KPV among bulk drug substances nominated but withdrawn (previously in category 2, withdrawn by the nominators) on its page of bulk drug substances that may present significant safety risks in compounding (content current as of 2026-04-22).FDA
FDA advisory committee calendar page for the July 23-24, 2026 Pharmacy Compounding Advisory Committee meeting lists BPC-157 and KPV on the July 23 agenda.FDA
FDA briefing document for the July 23-24, 2026 Pharmacy Compounding Advisory Committee meeting lists briefing packages for BPC-157 and KPV.FDA
FDA briefing document on KPV for the July 23-24, 2026 Pharmacy Compounding Advisory Committee meeting states KPV is promoted as a compounded drug product in combination with BPC-157, TB-500, AOD9604 and Follistatin-344.FDA
FDA presentations for the July 23, 2026 Pharmacy Compounding Advisory Committee meeting list BPC-157 and KPV among the bulk drug substances discussed.FDA

Get updates on BPC-157 / KPV stack

We'll store your email, your state, the page you're on and the peptides selected below (pre-selected from this page; untick any). Together these can reveal health interests. We use them only for what you tick below and to count sign-ups by state and peptide, without emails, to plan where the clinic opens and for reports that show only totals. Our hosting, database and email providers handle them for us. We pass them to a doctor or clinic only if you tick that box, and we don't sell them. Withdraw anytime with the unsubscribe link or at hello@ellumclinic.com. Consumer Health Data Privacy Policy

Ellum's sign-ups are for adults 18 and over.

Peptides: BPC-157 / KPV stack (1 selected) · edit
Peptides you're interested in
What we may email you about
More options (optional): research, doctor contact, paid offers

The research on BPC-157 / KPV stack

Key facts

Also known as: bpc kpv, bpc-157 kpv

Parts
BPC-157 and KPV
Route
injectable;oral;topical

References

  1. pubmed.ncbi.nlm.nih.gov/30915550
  2. clinicaltrials.gov/study/NCT02637284
  3. clinicaltrials.gov/study/NCT07803250
  4. www.fda.gov
  5. www.fda.gov
  6. pubmed.ncbi.nlm.nih.gov/21030672
  7. pubmed.ncbi.nlm.nih.gov/14554208
  8. pubmed.ncbi.nlm.nih.gov/25995620
  9. pubmed.ncbi.nlm.nih.gov/24304574
  10. pubmed.ncbi.nlm.nih.gov/33051481
  11. pubmed.ncbi.nlm.nih.gov/9298922
  12. pubmed.ncbi.nlm.nih.gov/31976029
  13. pubmed.ncbi.nlm.nih.gov/21840572
  14. pubmed.ncbi.nlm.nih.gov/30690000
  15. pubmed.ncbi.nlm.nih.gov/21295044
  16. pubmed.ncbi.nlm.nih.gov/9403788

Status sources

Sources as of October 4, 2026

  1. FDA: www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
  2. FDA: www.fda.gov/media/193346/download

What this doesn’t establish

Results for one compound don't tell you what the two do together.

The BPC-157 evidence does not establish that any effect seen in rats, chickens or lab cells happens in people.[1][16] A 2019 review states that efficacy is yet to be confirmed in humans, so no benefit for any condition in people has been shown.[1]